Clinical Presentations and Outcomes of Children in Canada with Recurrent Invasive Pneumococcal Disease from the IMPACT Surveillance Network

Yousif Murad; Te Yu Hung; Manish Sadarangani; Shaun K. Morris; Nicole Le Saux; Otto G. Vanderkooi; James D. Kellner; Gregory J. Tyrrell; Irene Martin; Walter Demczuk; Scott A. Halperin; Julie A. Bettinger; N. Bridger; Cheryl Foo; S. A. Halperin; K. A. Top; R. Thibeault; D. Moore; J. Papenburg; M. Lebel; N. Le Saux; S. Morris; J. Embree; B. Tan; Athena McConnell; T. Jadavji; C. Constantinescu; W. Vaudry; D. Scheifele; M. Sadarangani; J. Bettinger; L. Sauvé

doi:10.1097/INF.0000000000003454

Clinical Presentations and Outcomes of Children in Canada with Recurrent Invasive Pneumococcal Disease from the IMPACT Surveillance Network

Yousif Murad, Te Yu Hung, Manish Sadarangani, Shaun K. Morris, Nicole Le Saux, Otto G. Vanderkooi, James D. Kellner, Gregory J. Tyrrell, Irene Martin, Walter Demczuk, Scott A. Halperin, Julie A. Bettinger, N. Bridger, Cheryl Foo, S. A. Halperin, K. A. Top, R. Thibeault, D. Moore, J. Papenburg, M. LebelN. Le Saux, S. Morris, J. Embree, B. Tan, Athena McConnell, T. Jadavji, C. Constantinescu, W. Vaudry, D. Scheifele, M. Sadarangani, J. Bettinger, L. Sauvé

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Background: Invasive pneumococcal disease due to Streptococcus pneumoniae can cause mortality and severe morbidity due to sepsis, meningitis and pneumonia, particularly in young children and the elderly. Recurrent invasive pneumococcal disease is rare yet serious sequelae of invasive pneumococcal disease that is associated with the immunocompromised and leads to a high mortality rate. Method: This retrospective study reviewed recurrent invasive pneumococcal disease cases from the Canadian Immunization Monitoring Program, ACTive IMPACT between 1991 and 2019, an active network for surveillance of vaccine-preventable diseases and adverse events following immunization for children ages 0-16 years. Data were collected from 12 pediatric tertiary care hospitals across all 3 eras of public pneumococcal conjugate vaccine implementation in Canada. Results: The survival rate within our cohort of 180 recurrent invasive pneumococcal disease cases was 98.3%. A decrease of 26.4% in recurrent invasive pneumococcal disease due to vaccine serotypes was observed with pneumococcal vaccine introduction. There was also a 69.0% increase in the rate of vaccination in children with preexisting medical conditions compared with their healthy peers. Conclusion: The decrease in recurrent invasive pneumococcal disease due to vaccine-covered serotypes has been offset by an increase of non-vaccine serotypes in this sample of Canadian children.

Original language	English
Pages (from-to)	E166-E171
Journal	Pediatric Infectious Disease Journal
Volume	41
Issue number	4
DOIs	https://doi.org/10.1097/INF.0000000000003454
Publication status	Published - Apr 1 2022
Externally published	Yes

Bibliographical note

Funding Information:
S.H. has received funding for clinical trials and have served on ad hoc advisory boards for Pfizer, the manufacturer of PCV7 and PCV13, unrelated to pneumococcal disease. M.S. is supported via salary awards from the BC Children’s Hospital Foundation, the Canadian Child Health Clinician Scientist Program and the Michael Smith Foundation for Health Research. M.S. has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. G.T. has received funding for pneumococcal studies from Merck and has served on a Pfizer advisory committee for vaccines. S.M. has participated on an advisory board for Pfizer, is an investigator on an investigator-led project funded by Pfizer, and has received personal fees from Johnson and Johnson China and GlaxoSmithKline outside the submitted work.

Publisher Copyright:
© 2022 The Authors.

ASJC Scopus Subject Areas

Pediatrics, Perinatology, and Child Health
Microbiology (medical)
Infectious Diseases

PubMed: MeSH publication types

Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/INF.0000000000003454

Cite this

Murad, Y., Hung, T. Y., Sadarangani, M., Morris, S. K., Le Saux, N., Vanderkooi, O. G., Kellner, J. D., Tyrrell, G. J., Martin, I., Demczuk, W., Halperin, S. A., Bettinger, J. A., Bridger, N., Foo, C., Halperin, S. A., Top, K. A., Thibeault, R., Moore, D., Papenburg, J., ... Sauvé, L. (2022). Clinical Presentations and Outcomes of Children in Canada with Recurrent Invasive Pneumococcal Disease from the IMPACT Surveillance Network. Pediatric Infectious Disease Journal, 41(4), E166-E171. https://doi.org/10.1097/INF.0000000000003454

Murad, Y, Hung, TY, Sadarangani, M, Morris, SK, Le Saux, N, Vanderkooi, OG, Kellner, JD, Tyrrell, GJ, Martin, I, Demczuk, W, Halperin, SA, Bettinger, JA, Bridger, N, Foo, C, Halperin, SA, Top, KA, Thibeault, R, Moore, D, Papenburg, J, Lebel, M, Le Saux, N, Morris, S, Embree, J, Tan, B, McConnell, A, Jadavji, T, Constantinescu, C, Vaudry, W, Scheifele, D, Sadarangani, M, Bettinger, J & Sauvé, L 2022, 'Clinical Presentations and Outcomes of Children in Canada with Recurrent Invasive Pneumococcal Disease from the IMPACT Surveillance Network', Pediatric Infectious Disease Journal, vol. 41, no. 4, pp. E166-E171. https://doi.org/10.1097/INF.0000000000003454

@article{10a252e9786049ab81998103ce5371f1,

title = "Clinical Presentations and Outcomes of Children in Canada with Recurrent Invasive Pneumococcal Disease from the IMPACT Surveillance Network",

abstract = "Background: Invasive pneumococcal disease due to Streptococcus pneumoniae can cause mortality and severe morbidity due to sepsis, meningitis and pneumonia, particularly in young children and the elderly. Recurrent invasive pneumococcal disease is rare yet serious sequelae of invasive pneumococcal disease that is associated with the immunocompromised and leads to a high mortality rate. Method: This retrospective study reviewed recurrent invasive pneumococcal disease cases from the Canadian Immunization Monitoring Program, ACTive IMPACT between 1991 and 2019, an active network for surveillance of vaccine-preventable diseases and adverse events following immunization for children ages 0-16 years. Data were collected from 12 pediatric tertiary care hospitals across all 3 eras of public pneumococcal conjugate vaccine implementation in Canada. Results: The survival rate within our cohort of 180 recurrent invasive pneumococcal disease cases was 98.3%. A decrease of 26.4% in recurrent invasive pneumococcal disease due to vaccine serotypes was observed with pneumococcal vaccine introduction. There was also a 69.0% increase in the rate of vaccination in children with preexisting medical conditions compared with their healthy peers. Conclusion: The decrease in recurrent invasive pneumococcal disease due to vaccine-covered serotypes has been offset by an increase of non-vaccine serotypes in this sample of Canadian children. ",

author = "Yousif Murad and Hung, {Te Yu} and Manish Sadarangani and Morris, {Shaun K.} and {Le Saux}, Nicole and Vanderkooi, {Otto G.} and Kellner, {James D.} and Tyrrell, {Gregory J.} and Irene Martin and Walter Demczuk and Halperin, {Scott A.} and Bettinger, {Julie A.} and N. Bridger and Cheryl Foo and Halperin, {S. A.} and Top, {K. A.} and R. Thibeault and D. Moore and J. Papenburg and M. Lebel and {Le Saux}, N. and S. Morris and J. Embree and B. Tan and Athena McConnell and T. Jadavji and C. Constantinescu and W. Vaudry and D. Scheifele and M. Sadarangani and J. Bettinger and L. Sauv{\'e}",

note = "Funding Information: S.H. has received funding for clinical trials and have served on ad hoc advisory boards for Pfizer, the manufacturer of PCV7 and PCV13, unrelated to pneumococcal disease. M.S. is supported via salary awards from the BC Children{\textquoteright}s Hospital Foundation, the Canadian Child Health Clinician Scientist Program and the Michael Smith Foundation for Health Research. M.S. has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. G.T. has received funding for pneumococcal studies from Merck and has served on a Pfizer advisory committee for vaccines. S.M. has participated on an advisory board for Pfizer, is an investigator on an investigator-led project funded by Pfizer, and has received personal fees from Johnson and Johnson China and GlaxoSmithKline outside the submitted work. Publisher Copyright: {\textcopyright} 2022 The Authors.",

year = "2022",

month = apr,

day = "1",

doi = "10.1097/INF.0000000000003454",

language = "English",

volume = "41",

pages = "E166--E171",

journal = "Pediatric Infectious Disease Journal",

issn = "0891-3668",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Clinical Presentations and Outcomes of Children in Canada with Recurrent Invasive Pneumococcal Disease from the IMPACT Surveillance Network

AU - Murad, Yousif

AU - Hung, Te Yu

AU - Sadarangani, Manish

AU - Morris, Shaun K.

AU - Le Saux, Nicole

AU - Vanderkooi, Otto G.

AU - Kellner, James D.

AU - Tyrrell, Gregory J.

AU - Martin, Irene

AU - Demczuk, Walter

AU - Halperin, Scott A.

AU - Bettinger, Julie A.

AU - Bridger, N.

AU - Foo, Cheryl

AU - Halperin, S. A.

AU - Top, K. A.

AU - Thibeault, R.

AU - Moore, D.

AU - Papenburg, J.

AU - Lebel, M.

AU - Le Saux, N.

AU - Morris, S.

AU - Embree, J.

AU - Tan, B.

AU - McConnell, Athena

AU - Jadavji, T.

AU - Constantinescu, C.

AU - Vaudry, W.

AU - Scheifele, D.

AU - Sadarangani, M.

AU - Bettinger, J.

AU - Sauvé, L.

N1 - Funding Information: S.H. has received funding for clinical trials and have served on ad hoc advisory boards for Pfizer, the manufacturer of PCV7 and PCV13, unrelated to pneumococcal disease. M.S. is supported via salary awards from the BC Children’s Hospital Foundation, the Canadian Child Health Clinician Scientist Program and the Michael Smith Foundation for Health Research. M.S. has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. G.T. has received funding for pneumococcal studies from Merck and has served on a Pfizer advisory committee for vaccines. S.M. has participated on an advisory board for Pfizer, is an investigator on an investigator-led project funded by Pfizer, and has received personal fees from Johnson and Johnson China and GlaxoSmithKline outside the submitted work. Publisher Copyright: © 2022 The Authors.

PY - 2022/4/1

Y1 - 2022/4/1

N2 - Background: Invasive pneumococcal disease due to Streptococcus pneumoniae can cause mortality and severe morbidity due to sepsis, meningitis and pneumonia, particularly in young children and the elderly. Recurrent invasive pneumococcal disease is rare yet serious sequelae of invasive pneumococcal disease that is associated with the immunocompromised and leads to a high mortality rate. Method: This retrospective study reviewed recurrent invasive pneumococcal disease cases from the Canadian Immunization Monitoring Program, ACTive IMPACT between 1991 and 2019, an active network for surveillance of vaccine-preventable diseases and adverse events following immunization for children ages 0-16 years. Data were collected from 12 pediatric tertiary care hospitals across all 3 eras of public pneumococcal conjugate vaccine implementation in Canada. Results: The survival rate within our cohort of 180 recurrent invasive pneumococcal disease cases was 98.3%. A decrease of 26.4% in recurrent invasive pneumococcal disease due to vaccine serotypes was observed with pneumococcal vaccine introduction. There was also a 69.0% increase in the rate of vaccination in children with preexisting medical conditions compared with their healthy peers. Conclusion: The decrease in recurrent invasive pneumococcal disease due to vaccine-covered serotypes has been offset by an increase of non-vaccine serotypes in this sample of Canadian children.

AB - Background: Invasive pneumococcal disease due to Streptococcus pneumoniae can cause mortality and severe morbidity due to sepsis, meningitis and pneumonia, particularly in young children and the elderly. Recurrent invasive pneumococcal disease is rare yet serious sequelae of invasive pneumococcal disease that is associated with the immunocompromised and leads to a high mortality rate. Method: This retrospective study reviewed recurrent invasive pneumococcal disease cases from the Canadian Immunization Monitoring Program, ACTive IMPACT between 1991 and 2019, an active network for surveillance of vaccine-preventable diseases and adverse events following immunization for children ages 0-16 years. Data were collected from 12 pediatric tertiary care hospitals across all 3 eras of public pneumococcal conjugate vaccine implementation in Canada. Results: The survival rate within our cohort of 180 recurrent invasive pneumococcal disease cases was 98.3%. A decrease of 26.4% in recurrent invasive pneumococcal disease due to vaccine serotypes was observed with pneumococcal vaccine introduction. There was also a 69.0% increase in the rate of vaccination in children with preexisting medical conditions compared with their healthy peers. Conclusion: The decrease in recurrent invasive pneumococcal disease due to vaccine-covered serotypes has been offset by an increase of non-vaccine serotypes in this sample of Canadian children.

UR - http://www.scopus.com/inward/record.url?scp=85127343766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127343766&partnerID=8YFLogxK

U2 - 10.1097/INF.0000000000003454

DO - 10.1097/INF.0000000000003454

M3 - Article

C2 - 35093996

AN - SCOPUS:85127343766

SN - 0891-3668

VL - 41

SP - E166-E171

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

IS - 4

ER -

Clinical Presentations and Outcomes of Children in Canada with Recurrent Invasive Pneumococcal Disease from the IMPACT Surveillance Network

Abstract

Bibliographical note

ASJC Scopus Subject Areas

PubMed: MeSH publication types

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this